Driven by demand for new materials with intriguing features, the discipline of materials science and technology is rapidly advancing and now makes a significant contribution to research in nanoscale science. A material is classified based on the number of dimensions outside the nanoscale range in which particles are contained. Artificial nanocrystals with confinement in all three dimensions and nanometer-scale electron-transport capabilities are called quantum dots (QDs). Because of their distinct physical and optical properties, QDs have captivated scientists worldwide since their discovery in 1981. Their potential for use in a variety of optical-based biological applications makes them extremely desirable. QDs, which are nanocrystals smaller than 10 nm, possess unique optical, electrical, and chemical properties due to quantum confinement. QDs can be synthesised via colloidal, hydrothermal, and biomimetic methods. They have potential uses in biosensors, bioimaging, wastewater treatment, drug delivery, and quantum computing. QDs’ basic composition, size, surface functionalization, and dose are the primary variables affecting their biocompatibility and toxicity. Potential toxicity from oxidative stress and heavy metal release can be significantly reduced by using appropriate surface coating and encapsulation techniques. In 2011, the first human clinical trial using QD technology was approved by the USFDA. This innovative phase I exploratory trial used silica-based near-infrared QDs in a small number of patients with melanoma. This review provides a basic introduction to QDs, their preparation process, drug release mechanism, applications, challenges, toxicity concerns, and clinical trials. The role of artificial intelligence (AI), machine learning (ML), and deep learning in QD design, optimization, biocompatibility enhancement, and augmentation of therapeutic performance has been the focus, leading to a novel perspective.